cas 887707-25-7|| where to buy 2-Chloro-5-iodo-3-(trifluoromethyl)pyridine

Produktname:2-Chloro-5-iodo-3-(trifluoromethyl)pyridine

IUPAC Name:2-chloro-5-iodo-3-(trifluoromethyl)pyridine

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM120826-10g	in stock	ƃƿƛ
CM120826-25g	in stock	ƛȐȡ
CM120826-100g	in stock	ƃƛƛȡ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 887707-25-7 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:887707-25-7; Molekulare Formel:C6H2ClF3IN; Schmelzpunkt:-; SMILES-Code:FC(C1=CC(I)=CN=C1Cl)(F)F; Dichte:

: Katalognummer:CM120826; Molekulargewicht:307.44; Siedepunkt:261.2°C at 760 mmHg; Mdl-Nr.:MFCD12024302; Lagerung:Keep in dark place, inert atmosphere, store at 2-8°C.

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: Apalutamide; Johnson & Johnson announced results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® (apalutamide) and androgen deprivation therapy (ADT) in patients with HRLPC who have undergone radical prostatectomy (RP). Following RP, patients who received the treatment regimen showed a 100% biochemical recurrence (BCR)–free rate at 24 months. ERLEADA® (apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.